Thus, in the context of diabetes, zinc-dependent drug targeting to β-cells could be improved by pharmacologically increasing β-cell zinc with a compound like GR-46611 and/or through insulin therapy to promote β-cell rest, boost insulin content and thus, zinc levels. This evidence concerns the gene INS and diabetes mellitus.